Trial Profile
ONO-7436 Phase 3 Study, A Multi-Center, Open Clinical Trial to Examine the Safety, Efficacy and Pharmacokinetics of ONO-7436 for the Prevention of Cancer Chemotherapy-Induced Nausea and Vomiting in Adolescent Patients with Malignant Tumor.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 May 2018
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 26 May 2016 New trial record